Modality
Peptide
MOA
GLP-1ag
Target
BCL-2
Pathway
RAS/MAPK
NBADPKD
Development Pipeline
Preclinical
~Nov 2015
→ ~Feb 2017
Phase 1
May 2017
→ Apr 2031
Phase 1Current
NCT06467452
2,124 pts·ADPKD
2025-03→2031-04·Terminated
NCT05552516
2,350 pts·NB
2017-05→2026-12·Completed
4,474 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-12-249mo awayPh2 Data· NB
2031-04-285.1y awayPh2 Data· ADPKD
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P1/2
Complet…
P1/2
Termina…
Catalysts
Ph2 Data
2026-12-24 · 9mo away
NB
Ph2 Data
2031-04-28 · 5.1y away
ADPKD
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06467452 | Phase 1/2 | ADPKD | Terminated | 2124 | FEV1 |
| NCT05552516 | Phase 1/2 | NB | Completed | 2350 | Safety |
Competitors (10)